TrialBMC cancer2020

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies.

Cornelis M van Tilburg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.